{
    "id": 104,
    "premise": "none",
    "hypothesis": "Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance.",
    "label": "entailment",
    "explanation": "an irreversible inhibitor that is targeted to the HER2 kinase domain\u2026 should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance.",
        "history explanation": [
            "0 iteration: an irreversible inhibitor that is targeted to the HER2 kinase domain\u2026 should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
            "1 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "2 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "3 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "4 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "5 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "6 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "7 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "8 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThe resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.",
            "9 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain.\nThere is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab.\nIf the HER2 V777L mutation is not directly related to trastuzumab resistance, then trastuzumab resistance is not present.\nIf a specific mechanism is identified due to the HER2 V777L mutation, then a treatment targeting this mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance.",
            "10 iteration: The HER2 V777L mutation, located in the intracellular kinase domain, does not directly affect trastuzumab binding to the extracellular kinase domain.\nTrastuzumab resistance may not solely be determined by the HER2 V777L mutation due to its location in the intracellular kinase domain."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* From the premise, we know about HER2 V777L. *)\\nfrom asm have \"HER2V777L x\" sledgehammer', 'solving time': 89.1583821773529, 'proof tactics': [], 'code': 'theory clinical_104_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Should :: \"event \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity\"\\n  HER2ActivatingMutation :: \"entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity\"\\n  IntracellularKinaseDomain :: \"entity\"\\n  May :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x HER2KinaseDomain \u2227 Should e \u2227 Overcome e \u2227 Resistance y \u2227 Trastuzumab y \u2227 InducedBy y HER2ActivatingMutation \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. HER2V777L x \u2227 Cause e \u2227 Resistance y \u2227 Trastuzumab y \u2227 BindsTo y ExtracellularKinaseDomain \u2227 Mutation z \u2227 In z IntracellularKinaseDomain \u2227 May e \u2227 Agent e x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HERV777L x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y z e. Targeting e \u2227 HERV777L x \u2227 Inhibitor y \u2227 Irreversible y \u2227 TyrosineKinase y \u2227 May e \u2227 Overcome e \u2227 Resistance z \u2227 Treatment z \u2227 Agent e x \u2227 Patient e z\"\\nproof -\\n  (* From the premise, we know about HER2 V777L. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L, cause resistance to trastuzumab) *)\\n  (* Both C and D are from explanatory sentence 2. *)\\n  (* We can infer that HER2 V777L causes resistance to trastuzumab. *)\\n  then have \"Cause e \u2227 Resistance z \u2227 Trastuzumab z \u2227 Agent e x\" <ATP>\\n  (* There is an explanatory sentence 1 that connects an irreversible inhibitor targeted to the HER2 kinase domain with overcoming trastuzumab resistance induced by a HER2-activating mutation. *)\\n  (* We need to find a connection between the HER2 V777L mutation and the treatment resistance. *)\\n  (* Since the mutation is in the intracellular kinase domain and trastuzumab binds to the extracellular kinase domain, we can infer that the mutation is not directly related to trastuzumab resistance. *)\\n  (* Therefore, we cannot directly link HER2 V777L to the treatment resistance based on the given information. *)\\n  (* Hence, we cannot prove the hypothesis with the provided information. *)\\n  (* Thus, the proof is not possible with the current knowledge. *)\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation\\nC: HER2 V777L\\nD: cause resistance to trastuzumab\\nE: trastuzumab binds to the extracellular kinase domain\\nF: mutation is in the intracellular kinase domain\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L, cause resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  As :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabBindsToExtracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  ResistanceInducedByHER2ActivatingMutation :: \"entity \u21d2 bool\"\\n  Related :: \"event \u21d2 bool\"\\n  Identify :: \"event \u21d2 bool\"\\n  SpecificMechanism :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TreatmentResistanceToTrastuzab :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2_V777L_Mutation x \u2227 IntracellularKinaseDomain y \u2227 TrastuzumabResistance z \u2227 Contribute e \u2227 \u00acDirectly e \u2227 Agent e x \u2227 Patient e z \u2227 As e TrastuzumabBindsToExtracellularKinaseDomain\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. ResistanceInducedByHER2ActivatingMutation x \u2227 HER2_V777L_Mutation y \u2227 \u00acRelated e \u2227 Directly e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Identify e \u2227 SpecificMechanism x \u2227 HER2_V777L_Mutation y \u2227 Lead e \u2227 Agent e y \u2227 Patient e z \u2227 TreatmentResistanceToTrastuzab z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2_V777L_Mutation x \u2227 IrreversibleTyrosineKinaseInhibitor y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting e \u2227 HER2_V777L_Mutation x \u2227 IrreversibleTyrosineKinaseInhibitor y \u2227 Overcome e \u2227 Agent e x \u2227 Patient e z \u2227 TreatmentResistance z\"\\nproof -\\n  (* From the premise, we have information about the HER2 V777L mutation and the irreversible tyrosine kinase inhibitor. *)\\n  from asm have \"HER2_V777L_Mutation x\" and \"IrreversibleTyrosineKinaseInhibitor y\" <ATP>\\n  \\n  (* We know from Explanation 1 that the HER2 V777L mutation may not directly contribute to trastuzumab resistance. *)\\n  (* There is a logical relation Implies(A, B), Implies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance) *)\\n  (* We can infer that the HER2 V777L mutation does not directly contribute to trastuzumab resistance. *)\\n  then have \"\u00acContribute e\" <ATP>\\n  \\n  (* From Explanation 3, we know that there is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\n  (* We can infer that there is a specific mechanism that leads to treatment resistance. *)\\n  then have \"Identify e \u2227 SpecificMechanism x \u2227 Lead e \u2227 TreatmentResistanceToTrastuzab z\" <ATP>\\n  \\n  (* Combining the above information, we can conclude that targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: may not directly contribute to trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: may not be directly related to the HER2 V777L mutation\\nF: there is a need to identify a specific mechanism\\nG: HER2 V777L mutation could lead to treatment resistance to trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance)\\n--------\\nImplies(B, Not(C))\\nImplies(may not directly contribute to trastuzumab resistance, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, may not be directly related to the HER2 V777L mutation)\\n--------\\nImplies(A, G)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, HER2 V777L mutation could lead to treatment resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(C, Not(A))\\nImplies(trastuzumab binds to the extracellular kinase domain, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(A, Not(C))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2 :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Not :: \"bool \u21d2 bool\"\\n  Reason :: \"event \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Related :: \"event \u21d2 bool\"\\n  Degree :: \"event \u21d2 entity \u21d2 bool\"\\n  Comparison :: \"event \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Identify :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TyrosineKinase :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2 x \u2227 V777L x \u2227 Mutation x \u2227 Located x intracellular kinase domain \u2227 Contribute e \u2227 Agent e x \u2227 Patient e trastuzumab \u2227 Not (Contribute e) \u2227 Reason e trastuzumab binds extracellular kinase domain\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Resistance x \u2227 InducedBy x HER2-activating mutation \u2227 Related e \u2227 Not (Related e) \u2227 Degree e directly \u2227 Comparison e HER2 V777L mutation\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Mechanism x \u2227 Identify e \u2227 Agent e x \u2227 Through e HER2 V777L mutation \u2227 Lead e \u2227 Agent e HER2 V777L mutation \u2227 Patient e treatment resistance trastuzumab\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Resistance x \u2227 InducedBy x HER2-activating mutation\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting x HERV777L y z \u2227 Inhibitor y \u2227 Irreversible y \u2227 TyrosineKinase y \u2227 Overcome e \u2227 Agent e x \u2227 Patient e z \u2227 Resistance z \u2227 Treatment z\"\\nproof -\\n  (* From the premise, we know that there is resistance induced by a HER2-activating mutation. *)\\n  from asm have \"Resistance x\" and \"InducedBy x HER2-activating mutation\" <ATP>\\n  (* There is a logical relation Implies(D, A), Implies(resistance induced by a HER2-activating mutation, HER2 V777L mutation located in the intracellular kinase domain) *)\\n  (* Since there is resistance induced by a HER2-activating mutation, we can infer that the HER2 V777L mutation is located in the intracellular kinase domain. *)\\n  then have \"HER2 V777L x\" <ATP>\\n  (* There is a logical relation Implies(A, E), Implies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified) *)\\n  (* Given that the HER2 V777L mutation is located in the intracellular kinase domain, we can conclude that there is a specific mechanism identified. *)\\n  then have \"Mechanism x\" <ATP>\\n  (* From the explanation 3, we can see that the identified mechanism leads to treatment resistance to trastuzumab. *)\\n  then have \"Identify e\" and \"Through e HER2 V777L x\" and \"Lead e\" and \"Agent e HER2 V777L x\" and \"Patient e treatment resistance trastuzumab\" <ATP>\\n  (* The hypothesis states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  (* We can construct the required elements for the hypothesis. *)\\n  then have \"Targeting x HERV777L y z\" and \"Inhibitor y\" and \"Irreversible y\" and \"TyrosineKinase y\" and \"Overcome e\" and \"Agent e x\" and \"Patient e z\" and \"Resistance z\" and \"Treatment z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: specific mechanism identified\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab resistance))\\n--------\\nNot(D)\\nNot(resistance induced by a HER2-activating mutation)\\n--------\\nImplies(A, E)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(D))\\nImplies(Not(specific mechanism identified), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(E))\\nImplies(resistance induced by a HER2-activating mutation, Not(specific mechanism identified))\\n--------\\nImplies(D, A)\\nImplies(resistance induced by a HER2-activating mutation, HER2 V777L mutation located in the intracellular kinase domain)\\n--------\\nImplies(D, B)\\nImplies(resistance induced by a HER2-activating mutation, trastuzumab resistance)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(HER2 V777L mutation located in the intracellular kinase domain), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(trastuzumab resistance), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(B, Not(D))\\nImplies(trastuzumab resistance, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(A))\\nImplies(resistance induced by a HER2-activating mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(D, Not(B))\\nImplies(resistance induced by a HER2-activating mutation, Not(trastuzumab resistance))\\n--------\\nImplies(E, Not(D))\\nImplies(specific mechanism identified, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(A, Not(D))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, specific mechanism identified)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.164774417877197, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient e :: entity \\\\<Rightarrow> bool\\nOperand:   z :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_104_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2 :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Binds :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2ActivatingMutation :: \"entity\"\\n  Related :: \"event \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  RelatedTo :: \"event \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Identify :: \"event \u21d2 bool\"\\n  Specific :: \"entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2 x \u2227 V777L x \u2227 Mutation x \u2227 Located x IntracellularKinaseDomain \u2227 Contribute e \u2227 \u00acDirectly e \u2227 Agent e x \u2227 Patient e x \u2227 Resistance z \u2227 Trastuzumab z \u2227 Binds z ExtracellularKinaseDomain\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Resistance x \u2227 InducedBy x HER2ActivatingMutation \u2227 Related e \u2227 \u00acDirectly e \u2227 Agent e x \u2227 \u00acRelatedTo e HERV777L\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Mechanism x \u2227 Identify e \u2227 Specific x \u2227 Through e x \u2227 Lead e \u2227 Agent e HERV777L \u2227 Patient e z \u2227 Treatment z \u2227 Trastuzumab z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Targeting(x, HERV777L, y, z) \u2227 Inhibitor(y) \u2227 Irreversible(y) \u2227 TyrosineKinase(y) \u2227 Overcome(z)\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting(x, HERV777L, y, z) \u2227 Inhibitor(y) \u2227 Irreversible(y) \u2227 TyrosineKinase(y) \u2227 Overcome(e) \u2227 Agent e x \u2227 Patient e z \u2227 Resistance z \u2227 Treatment z\"\\nproof -\\n  (* From the premise, we have information about targeting, inhibitor, irreversible, tyrosine kinase, and overcoming. *)\\n  from asm have \"Targeting(x, HERV777L, y, z) \u2227 Inhibitor(y) \u2227 Irreversible(y) \u2227 TyrosineKinase(y) \u2227 Overcome(z)\" <ATP>\\n  (* There is a logical relation Implies(A, G), Implies(HER2 V777L mutation located in the intracellular kinase domain, HER2 V777L mutation could lead to treatment resistance to trastuzumab) *)\\n  (* We can infer that the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\n  then have \"HER2 V777L mutation could lead to treatment resistance to trastuzumab\" <ATP>\\n  (* The hypothesis involves resistance and treatment, which are related to the inferred information. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: may not directly contribute to trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: may not be directly related to the HER2 V777L mutation\\nF: there is a need to identify a specific mechanism\\nG: HER2 V777L mutation could lead to treatment resistance to trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance)\\n--------\\nImplies(B, C)\\nImplies(may not directly contribute to trastuzumab resistance, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, may not be directly related to the HER2 V777L mutation)\\n--------\\nImplies(A, G)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, HER2 V777L mutation could lead to treatment resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  As :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabBindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  IrreversibleTyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  Targeting :: \"event \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2_V777L_Mutation x \u2227 IntracellularKinaseDomain y \u2227 TrastuzumabResistance z \u2227 Contribute e \u2227 \u00acDirectly e \u2227 Patient e z \u2227 As e (TrastuzumabBindsTo x)\"\\n\\nconsts\\n  ResistanceInducedByHER2ActivatingMutation :: \"entity \u21d2 bool\"\\n  Related :: \"event \u21d2 bool\"\\n  Subject :: \"event \u21d2 entity \u21d2 bool\"\\n  SubjectComplement :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. ResistanceInducedByHER2ActivatingMutation x \u2227 HER2_V777L_Mutation y \u2227 Related e \u2227 \u00acDirectly e \u2227 Subject e x \u2227 SubjectComplement e y\"\\n\\nconsts\\n  SpecificMechanism :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  CouldLead :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  ToTrastuzumab :: \"entity \u21d2 bool\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Identify e \u2227 SpecificMechanism x \u2227 HER2_V777L_Mutation y \u2227 Lead e \u2227 CouldLead e \u2227 Patient e z \u2227 TreatmentResistance z \u2227 ToTrastuzumab z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Targeting(e) \u2227 HER2_V777L_Mutation(x) \u2227 IrreversibleTyrosineKinaseInhibitor(y) \u2227 Overcome(e) \u2227 Patient(e, z) \u2227 TreatmentResistance(z)\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting(e) \u2227 HER2_V777L_Mutation(x) \u2227 IrreversibleTyrosineKinaseInhibitor(y) \u2227 Overcome(e) \u2227 Patient(e, z) \u2227 TreatmentResistance(z)\"\\nproof -\\n  (* From the premise, we have information about targeting, HER2 V777L mutation, irreversible tyrosine kinase inhibitor, overcome, patient, and treatment resistance. *)\\n  from asm have \"Targeting(e) \u2227 HER2_V777L_Mutation(x) \u2227 IrreversibleTyrosineKinaseInhibitor(y) \u2227 Overcome(e) \u2227 Patient(e, z) \u2227 TreatmentResistance(z)\" <ATP>\\n  (* There is a logical relation Implies(A, Not(B)), Implies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab resistance)) *)\\n  (* We know that the HER2 V777L mutation may not directly contribute to trastuzumab resistance. *)\\n  (* This implies that the HER2 V777L mutation may not lead to treatment resistance. *)\\n  (* There is a derived implication Implies(Not(B), Not(D)), Implies(Not(trastuzumab resistance), Not(resistance induced by a HER2-activating mutation)) *)\\n  (* Therefore, the absence of trastuzumab resistance indicates the absence of resistance induced by a HER2-activating mutation. *)\\n  then have \"\u2203x y z e. Targeting(e) \u2227 HER2_V777L_Mutation(x) \u2227 IrreversibleTyrosineKinaseInhibitor(y) \u2227 Overcome(e) \u2227 Patient(e, z) \u2227 TreatmentResistance(z)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: specific mechanism identified\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab resistance))\\n--------\\nNot(D)\\nNot(resistance induced by a HER2-activating mutation)\\n--------\\nImplies(A, E)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(D))\\nImplies(Not(specific mechanism identified), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(E))\\nImplies(resistance induced by a HER2-activating mutation, Not(specific mechanism identified))\\n--------\\nImplies(D, A)\\nImplies(resistance induced by a HER2-activating mutation, HER2 V777L mutation located in the intracellular kinase domain)\\n--------\\nImplies(D, B)\\nImplies(resistance induced by a HER2-activating mutation, trastuzumab resistance)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(HER2 V777L mutation located in the intracellular kinase domain), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(trastuzumab resistance), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(B, Not(D))\\nImplies(trastuzumab resistance, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(A))\\nImplies(resistance induced by a HER2-activating mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(D, Not(B))\\nImplies(resistance induced by a HER2-activating mutation, Not(trastuzumab resistance))\\n--------\\nImplies(E, Not(D))\\nImplies(specific mechanism identified, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(A, Not(D))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, specific mechanism identified)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2 :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity\"\\n  BindsTo :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity\"\\n  ResistanceInducedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2ActivatingMutation :: \"entity\"\\n  Related :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity\"\\n  Identify :: \"event \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  ThroughWhich :: \"event \u21d2 entity \u21d2 bool\"\\n  LeadTo :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity\"\\n  ToTrastuzumab :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e. HER2 x \u2227 V777L x \u2227 Mutation x \u2227 Located x IntracellularKinaseDomain \u2227 Not(Contribute e) \u2227 Patient e TrastuzumabResistance \u2227 BindsTo w Trastuzumab ExtracellularKinaseDomain\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. ResistanceInducedBy x HER2ActivatingMutation \u2227 Not(Related e) \u2227 Patient e HER2V777L\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Identify e \u2227 Mechanism x \u2227 ThroughWhich e x \u2227 HER2V777L x \u2227 LeadTo e \u2227 Patient e TreatmentResistance \u2227 ToTrastuzumab e\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Targeting(x, HERV777L, y, z) \u2227 IrreversibleTyrosineKinaseInhibitor(y)\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting(x, HERV777L, y, z) \u2227 IrreversibleTyrosineKinaseInhibitor(y) \u2227 Overcome(e) \u2227 Patient(e, TreatmentResistance)\"\\nproof -\\n  (* From the premise, we have information about targeting the HER V777L mutation and using an irreversible tyrosine kinase inhibitor. *)\\n  from asm have \"Targeting(x, HERV777L, y, z) \u2227 IrreversibleTyrosineKinaseInhibitor(y)\" <ATP>\\n  (* There is a logical relation Implies(A, Not(B)), Implies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab resistance)) *)\\n  (* We know that the HER2 V777L mutation may not directly contribute to trastuzumab resistance. *)\\n  (* This implies that targeting the HER V777L mutation may help overcome trastuzumab resistance. *)\\n  then have \"Overcome(e)\" <ATP>\\n  (* We have shown that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome treatment resistance. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: specific mechanism identified\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab resistance))\\n--------\\nNot(D)\\nNot(resistance induced by a HER2-activating mutation)\\n--------\\nImplies(A, E)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(D))\\nImplies(Not(specific mechanism identified), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(E))\\nImplies(resistance induced by a HER2-activating mutation, Not(specific mechanism identified))\\n--------\\nImplies(D, A)\\nImplies(resistance induced by a HER2-activating mutation, HER2 V777L mutation located in the intracellular kinase domain)\\n--------\\nImplies(D, B)\\nImplies(resistance induced by a HER2-activating mutation, trastuzumab resistance)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(HER2 V777L mutation located in the intracellular kinase domain), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(trastuzumab resistance), Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(B, Not(D))\\nImplies(trastuzumab resistance, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, Not(A))\\nImplies(resistance induced by a HER2-activating mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(D, Not(B))\\nImplies(resistance induced by a HER2-activating mutation, Not(trastuzumab resistance))\\n--------\\nImplies(E, Not(D))\\nImplies(specific mechanism identified, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(A, Not(D))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(resistance induced by a HER2-activating mutation))\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, specific mechanism identified)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2 :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 string \u21d2 string \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  trastuzumabResistance :: \"entity\"\\n  Not :: \"bool \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 string \u21d2 string \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 string \u21d2 bool\"\\n  Related :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Specific :: \"entity \u21d2 bool\"\\n  Identify :: \"event \u21d2 bool\"\\n  Through :: \"entity \u21d2 entity \u21d2 bool\"\\n  LeadTo :: \"event \u21d2 string \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TyrosineKinase :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. HER2 x \u2227 V777L x \u2227 Mutation x \u2227 Located x intracellular kinaseDomain \u2227 Contribute e1 \u2227 Patient e1 trastuzumabResistance \u2227 Not(Contribute e2) \u2227 Patient e2 trastuzumabResistance \u2227 BindsTo trastuzumab extracellular kinaseDomain\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Resistance x \u2227 InducedBy x HER2 HER2 activatingMutation \u2227 Not(Related e1) \u2227 Patient e1 HER2V777L \u2227 Related e2 \u2227 Patient e2 HER2V777L\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Mechanism x \u2227 Specific x \u2227 Identify e \u2227 Patient e x \u2227 Through x HER2V777L \u2227 LeadTo e treatmentResistance trastuzumab\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Targeting(x, HER2V777L, y) \u2227 Inhibitor(y) \u2227 Irreversible(y) \u2227 TyrosineKinase(y)\"\\n shows \"\u2203x y z e. Targeting x HER2V777L y \u2227 Inhibitor y \u2227 Irreversible y \u2227 TyrosineKinase y \u2227 Overcome e \u2227 Patient e trastuzumabResistance\"\\nproof -\\n  (* From the premise, we have information about targeting, inhibitor, irreversible, and tyrosine kinase. *)\\n  from asm have \"Targeting(x, HER2V777L, y)\" and \"Inhibitor(y)\" and \"Irreversible(y)\" and \"TyrosineKinase(y)\" <ATP>\\n  (* There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\n  (* This implies that the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\n  from explanation_3 have \"Mechanism x \u2227 Specific x \u2227 Identify e \u2227 Patient e x \u2227 Through x HER2V777L \u2227 LeadTo e treatmentResistance trastuzumab\" <ATP>\\n  then have \"HER2V777L x\" <ATP>\\n  (* The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance. *)\\n  (* This implies that the HER2 V777L mutation does not directly contribute to trastuzumab resistance. *)\\n  from explanation_1 have \"HER2 x \u2227 V777L x \u2227 Mutation x \u2227 Located x intracellular kinaseDomain \u2227 Contribute e1 \u2227 Patient e1 trastuzumabResistance \u2227 Not(Contribute e2) \u2227 Patient e2 trastuzumabResistance \u2227 BindsTo trastuzumab extracellular kinaseDomain\" <ATP>\\n  then have \"Not(HER2V777L x)\" <ATP>\\n  (* Combining the above two inferences, we can conclude that the HER2 V777L mutation does not directly contribute to trastuzumab resistance but could lead to treatment resistance. *)\\n  then have \"HER2V777L x \u2227 Not(HER2V777L x)\" <ATP>\\n  (* This leads to a contradiction, which allows us to derive the desired conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: may not directly contribute to trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: may not be directly related to the HER2 V777L mutation\\nF: there is a need to identify a specific mechanism\\nG: HER2 V777L mutation could lead to treatment resistance to trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance)\\n--------\\nImplies(B, Not(C))\\nImplies(may not directly contribute to trastuzumab resistance, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, may not be directly related to the HER2 V777L mutation)\\n--------\\nImplies(E, Not(A))\\nImplies(may not be directly related to the HER2 V777L mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(F, G)\\nImplies(there is a need to identify a specific mechanism, HER2 V777L mutation could lead to treatment resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(C, Not(A))\\nImplies(trastuzumab binds to the extracellular kinase domain, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(D, Not(A))\\nImplies(resistance induced by a HER2-activating mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(A, Not(C))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(A, Not(D))\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, Not(resistance induced by a HER2-activating mutation))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  NotDirectlyContribute :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  As :: \"entity \u21d2 entity \u21d2 bool\"\\n  ResistanceInducedBy :: \"entity \u21d2 bool\"\\n  HER2ActivatingMutation :: \"entity \u21d2 bool\"\\n  NotDirectlyRelated :: \"event \u21d2 bool\"\\n  Need :: \"entity \u21d2 bool\"\\n  Identify :: \"entity \u21d2 bool\"\\n  SpecificMechanism :: \"entity \u21d2 bool\"\\n  LeadTo :: \"event \u21d2 bool\"\\n  ToIdentify :: \"event \u21d2 entity \u21d2 bool\"\\n  ThroughWhich :: \"entity \u21d2 entity \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 entity \u21d2 bool\"\\n  IrreversibleTyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2_V777L_Mutation x \u2227 LocatedIn x IntracellularKinaseDomain \u2227 NotDirectlyContribute e \u2227 Agent e x \u2227 Patient e TrastuzumabResistance \u2227 BindsTo y ExtracellularKinaseDomain \u2227 As x y\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. ResistanceInducedBy x \u2227 HER2ActivatingMutation x \u2227 NotDirectlyRelated e \u2227 Agent e x \u2227 Patient e HER2_V777L_Mutation\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Need x \u2227 Identify y \u2227 SpecificMechanism z \u2227 LeadTo e \u2227 Agent e HER2_V777L_Mutation \u2227 Patient e TreatmentResistance \u2227 ToIdentify x z \u2227 ThroughWhich z y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2_V777L_Mutation x \u2227 IrreversibleTyrosineKinaseInhibitor y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting x y \u2227 HER2_V777L_Mutation y \u2227 IrreversibleTyrosineKinaseInhibitor z \u2227 Overcome e \u2227 Agent e x \u2227 Patient e TreatmentResistance\"\\nproof -\\n  (* From the premise, we have information about the HER2 V777L mutation and the irreversible tyrosine kinase inhibitor. *)\\n  from asm have \"HER2_V777L_Mutation x\" and \"IrreversibleTyrosineKinaseInhibitor y\" <ATP>\\n  (* There is a logical relation Implies(A, B), Implies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance) *)\\n  (* A is from explanatory sentence 1, B is from explanatory sentence 1. *)\\n  (* We can infer that the HER2 V777L mutation may not directly contribute to trastuzumab resistance. *)\\n  then have \"NotDirectlyContribute e\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(may not directly contribute to trastuzumab resistance, trastuzumab binds to the extracellular kinase domain) *)\\n  (* We can infer that trastuzumab binds to the extracellular kinase domain. *)\\n  then have \"BindsTo y ExtracellularKinaseDomain\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(HER2 V777L mutation located in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain) *)\\n  (* We can conclude that the HER2 V777L mutation is related to trastuzumab binding to the extracellular kinase domain. *)\\n  then have \"As x y\" <ATP>\\n  (* There is a logical relation Implies(E, G), Implies(may not be directly related to the HER2 V777L mutation, HER2 V777L mutation could lead to treatment resistance to trastuzumab) *)\\n  (* We can deduce that the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\n  then have \"HER2_V777L_Mutation y \u2227 TreatmentResistance\" <ATP>\\n  (* We have the necessary elements to prove the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: may not directly contribute to trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: may not be directly related to the HER2 V777L mutation\\nF: there is a need to identify a specific mechanism\\nG: HER2 V777L mutation could lead to treatment resistance to trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance)\\n--------\\nImplies(B, C)\\nImplies(may not directly contribute to trastuzumab resistance, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(D, E)\\nImplies(resistance induced by a HER2-activating mutation, may not be directly related to the HER2 V777L mutation)\\n--------\\nImplies(E, G)\\nImplies(may not be directly related to the HER2 V777L mutation, HER2 V777L mutation could lead to treatment resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(A))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(A, C)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(D, G)\\nImplies(resistance induced by a HER2-activating mutation, HER2 V777L mutation could lead to treatment resistance to trastuzumab)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(HER2 V777L mutation could lead to treatment resistance to trastuzumab), Not(resistance induced by a HER2-activating mutation))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(A, Not(C)), Implies(HER2 V777L mutation located in the intracellular kinase domain and not trastuzumab binds to the extracellular kinase domain, not trastuzumab resistance) *)\\n(* Since the HER2 V777L mutation is not directly contributing to trastuzumab resistance, we can infer not trastuzumab resistance. *)\\nthen have \"\u00acTreatmentResistance z\" sledgehammer', 'solving time': 118.69495677947998, 'proof tactics': [], 'code': 'theory clinical_104_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity\"\\n  ResistanceInducedByHER2ActivatingMutation :: \"entity \u21d2 bool\"\\n  Related :: \"event \u21d2 bool\"\\n  RelatedTo :: \"event \u21d2 entity \u21d2 bool\"\\n  SpecificMechanism :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  Identify :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2_V777L_Mutation x \u2227 IntracellularKinaseDomain y \u2227 TrastuzumabResistance z \u2227 Contribute e \u2227 \u00acDirectly e \u2227 Patient e z \u2227 Bind e \u2227 Agent e z \u2227 To e ExtracellularKinaseDomain z\"\\n\\n(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. ResistanceInducedByHER2ActivatingMutation x \u2227 \u00acRelated e \u2227 Directly e \u2227 HER2_V777L_Mutation z \u2227 RelatedTo e z\"\\n\\n(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Identify e \u2227 SpecificMechanism x \u2227 HER2_V777L_Mutation y \u2227 Lead e \u2227 Patient e z \u2227 TreatmentResistance z \u2227 To e z Trastuzumab\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2_V777L_Mutation x \u2227 IrreversibleTyrosineKinaseInhibitor y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting e \u2227 HER2_V777L_Mutation x \u2227 IrreversibleTyrosineKinaseInhibitor y \u2227 Overcome e \u2227 Patient e z \u2227 TreatmentResistance z\"\\nproof -\\n  (* From the premise, we have information about the HER2 V777L mutation and the irreversible tyrosine kinase inhibitor. *)\\n  from asm have \"HER2_V777L_Mutation x\" and \"IrreversibleTyrosineKinaseInhibitor y\" <ATP>\\n  \\n  (* There is a logical relation Implies(A, E), Implies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified) *)\\n  (* We can infer that a specific mechanism is identified due to the HER2 V777L mutation. *)\\n  then have \"SpecificMechanism x\" <ATP>\\n  \\n  (* There is a logical relation Implies(A, Not(C)), Implies(HER2 V777L mutation located in the intracellular kinase domain and not trastuzumab binds to the extracellular kinase domain, not trastuzumab resistance) *)\\n  (* Since the HER2 V777L mutation is not directly contributing to trastuzumab resistance, we can infer not trastuzumab resistance. *)\\n  then have \"\u00acTreatmentResistance z\" <ATP>\\n  \\n  (* We have the information about the HER2 V777L mutation, irreversible tyrosine kinase inhibitor, and the absence of treatment resistance. *)\\n  (* Therefore, we can conclude the hypothesis that targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: resistance induced by a HER2-activating mutation\\nE: specific mechanism identified\\n\\nLogical Relations:\\nImplies(And(A, Not(C)), Not(B))\\nImplies(A & ~C, Not(trastuzumab resistance))\\n--------\\nImplies(D, Not(A))\\nImplies(resistance induced by a HER2-activating mutation, Not(HER2 V777L mutation located in the intracellular kinase domain))\\n--------\\nImplies(A, E)\\nImplies(HER2 V777L mutation located in the intracellular kinase domain, specific mechanism identified)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* The HER2 V777L mutation is not directly related to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\n(* There is a logical relation Implies(A, C), Implies(HER2 V777L mutation located in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain) *)\\n(* Since the mutation does not directly contribute to trastuzumab resistance, we can infer Not(B) from Not(A) *)\\nhave \"\u00acTreatmentResistance z\" if \"HERMutation x\" for x z sledgehammer', 'solving time': 88.41877603530884, 'proof tactics': [], 'code': 'theory clinical_104_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  AdultSponges :: \"entity \u21d2 bool\"\\n  Eggs :: \"entity \u21d2 bool\"\\n  Sperm :: \"entity \u21d2 bool\"\\n  Gametes :: \"entity \u21d2 bool\"\\n  Produce :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  HERMutation :: \"entity \u21d2 bool\"\\n  TyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Adult sponges produce eggs and sperm. *)\\naxiomatization where\\n  explanation_1: \"\u2200x. AdultSponges x \u27f6 (\u2203e y z. Eggs y \u2227 Sperm z \u2227 Produce e \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z)\"\\n\\n(* Explanation 2: Sperm and eggs are cells known as gametes. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Sperm x \u2227 Eggs y \u27f6 Gametes x \u2227 Gametes y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"True\"\\n  shows \"\u2203x y z e. HERMutation x \u2227 TyrosineKinaseInhibitor y \u2227 TreatmentResistance z \u2227 Overcome e \u2227 Target e x \u2227 With e y \u2227 Agent e x \u2227 Patient e z\"\\nproof -\\n  (* The HER2 V777L mutation is not directly related to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)\\n  (* There is a logical relation Implies(A, C), Implies(HER2 V777L mutation located in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain) *)\\n  (* Since the mutation does not directly contribute to trastuzumab resistance, we can infer Not(B) from Not(A) *)\\n  have \"\u00acTreatmentResistance z\" if \"HERMutation x\" for x z <ATP>\\n  \\n  (* If a specific mechanism is identified due to the HER2 V777L mutation, then a treatment targeting this mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  (* There is a logical relation Implies(D, F), Implies(identify a specific mechanism, treatment targeting HER2 V777L mutation with an irreversible tyrosine kinase inhibitor) *)\\n  (* If a specific mechanism is identified, we can infer treatment resistance can be overcome. *)\\n  have \"\u2203x y z e. HERMutation x \u2227 TyrosineKinaseInhibitor y \u2227 \u00acTreatmentResistance z \u2227 Overcome e \u2227 Target e x \u2227 With e y \u2227 Agent e x \u2227 Patient e z\" if \"D\" for x y z e <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation located in the intracellular kinase domain\\nB: trastuzumab resistance\\nC: trastuzumab binds to the extracellular kinase domain\\nD: identify a specific mechanism\\nE: treatment resistance to trastuzumab\\nF: treatment targeting HER2 V777L mutation with an irreversible tyrosine kinase inhibitor\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Mutation :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Domain :: \"entity \u21d2 bool\"\\n  Kinase :: \"entity \u21d2 bool\"\\n  Intracellular :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Affect :: \"entity \u21d2 bool\"\\n  Not :: \"entity \u21d2 bool\"\\n  Binding :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  NotSolely :: \"entity \u21d2 bool\"\\n  Determine :: \"event \u21d2 bool\"\\n  May :: \"event \u21d2 bool\"\\n  DueTo :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, does not directly affect trastuzumab binding to the extracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Domain y \u2227 Kinase y \u2227 Intracellular y \u2227 Location e \u2227 In x y \u2227 Affect e \u2227 Not (Affect e) \u2227 Binding z \u2227 Trastuzumab z \u2227 Domain z \u2227 Extracellular z \u2227 To z y\"\\n\\n(* Explanation 2: Trastuzumab resistance may not solely be determined by the HER2 V777L mutation due to its location in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e. Resistance x \u2227 Trastuzumab y \u2227 NotSolely w \u2227 Determine e \u2227 May e \u2227 Mutation z \u2227 HER2 z \u2227 V777L z \u2227 Location w \u2227 Domain w \u2227 Kinase w \u2227 Intracellular w \u2227 In z w \u2227 DueTo e w\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Inhibitor y \u2227 TyrosineKinase y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n shows \"\u2203x y z e. Targeting e \u2227 Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Inhibitor y \u2227 TyrosineKinase y \u2227 Irreversible y \u2227 Overcome z \u2227 TreatmentResistance z \u2227 Agent z x \u2227 Patient z y \u2227 With z y\"\\nproof -\\n  (* From the premise, we know about the mutation, HER2, V777L, inhibitor, and tyrosine kinase. *)\\n  from asm have \"Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Inhibitor y \u2227 TyrosineKinase y\" <ATP>\\n  (* We have the explanatory sentence 1 stating that the HER2 V777L mutation does not directly affect trastuzumab binding to the extracellular kinase domain. *)\\n  (* There is a logical relation Implies(A, Not(C)), Implies(HER2 V777L mutation, Not(directly affect trastuzumab binding to the extracellular kinase domain)) *)\\n  (* Since the mutation does not directly affect trastuzumab binding, we can infer trastuzumab resistance. *)\\n  then have \"Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Inhibitor y \u2227 TyrosineKinase y \u2227 TreatmentResistance z\" <ATP>\\n  (* We also have the explanatory sentence 2 indicating that trastuzumab resistance may not solely be determined by the HER2 V777L mutation. *)\\n  (* There is a logical relation Implies(D, Not(E)), Implies(trastuzumab resistance, Not(solely be determined by the HER2 V777L mutation)) *)\\n  (* As trastuzumab resistance may not solely be determined by the mutation, we can conclude that targeting the mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  then have \"Mutation x \u2227 HER2 x \u2227 V777L x \u2227 Inhibitor y \u2227 TyrosineKinase y \u2227 TreatmentResistance z \u2227 Targeting e \u2227 Irreversible y \u2227 Overcome z \u2227 Agent z x \u2227 Patient z y \u2227 With z y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L mutation\\nB: located in the intracellular kinase domain\\nC: directly affect trastuzumab binding to the extracellular kinase domain\\nD: trastuzumab resistance\\nE: solely be determined by the HER2 V777L mutation\\n\\nLogical Relations:\\nNot(A)\\nNot(HER2 V777L mutation)\\n--------\\nImplies(A, B)\\nImplies(HER2 V777L mutation, located in the intracellular kinase domain)\\n--------\\nNot(C)\\nNot(directly affect trastuzumab binding to the extracellular kinase domain)\\n--------\\nImplies(A, Not(C))\\nImplies(HER2 V777L mutation, Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(A, D)\\nImplies(HER2 V777L mutation, trastuzumab resistance)\\n--------\\nNot(E)\\nNot(solely be determined by the HER2 V777L mutation)\\n--------\\nImplies(A, Not(E))\\nImplies(HER2 V777L mutation, Not(solely be determined by the HER2 V777L mutation))\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(E))\\nImplies(Not(trastuzumab resistance), Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(D, Not(E))\\nImplies(trastuzumab resistance, Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(HER2 V777L mutation), Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(solely be determined by the HER2 V777L mutation), Not(HER2 V777L mutation))\\n--------\\nImplies(C, Not(E))\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(B, Not(C))\\nImplies(located in the intracellular kinase domain, Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(A, Not(B))\\nImplies(HER2 V777L mutation, Not(located in the intracellular kinase domain))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(directly affect trastuzumab binding to the extracellular kinase domain), Not(HER2 V777L mutation))\\n--------\\nImplies(C, A)\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, HER2 V777L mutation)\\n--------\\nImplies(C, B)\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, located in the intracellular kinase domain)\\n--------\\nImplies(A, C)\\nImplies(HER2 V777L mutation, directly affect trastuzumab binding to the extracellular kinase domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(located in the intracellular kinase domain), Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(C, D)\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, trastuzumab resistance)\\n--------\\nImplies(C, Not(B))\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, Not(located in the intracellular kinase domain))\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(directly affect trastuzumab binding to the extracellular kinase domain), Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(A, Not(D))\\nImplies(HER2 V777L mutation, Not(trastuzumab resistance))\\n--------\\nImplies(B, Not(A))\\nImplies(located in the intracellular kinase domain, Not(HER2 V777L mutation))\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(trastuzumab resistance), Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(A, E)\\nImplies(HER2 V777L mutation, solely be determined by the HER2 V777L mutation)\\n--------\\nImplies(C, Not(D))\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, Not(trastuzumab resistance))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(HER2 V777L mutation), Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(E, A)\\nImplies(solely be determined by the HER2 V777L mutation, HER2 V777L mutation)\\n--------\\nImplies(E, B)\\nImplies(solely be determined by the HER2 V777L mutation, located in the intracellular kinase domain)\\n--------\\nImplies(B, Not(E))\\nImplies(located in the intracellular kinase domain, Not(solely be determined by the HER2 V777L mutation))\\n--------\\nImplies(D, Not(C))\\nImplies(trastuzumab resistance, Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(E, D)\\nImplies(solely be determined by the HER2 V777L mutation, trastuzumab resistance)\\n--------\\nImplies(C, E)\\nImplies(directly affect trastuzumab binding to the extracellular kinase domain, solely be determined by the HER2 V777L mutation)\\n--------\\nImplies(E, Not(B))\\nImplies(solely be determined by the HER2 V777L mutation, Not(located in the intracellular kinase domain))\\n--------\\nImplies(E, C)\\nImplies(solely be determined by the HER2 V777L mutation, directly affect trastuzumab binding to the extracellular kinase domain)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(solely be determined by the HER2 V777L mutation), Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(located in the intracellular kinase domain), Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\nImplies(D, Not(A))\\nImplies(trastuzumab resistance, Not(HER2 V777L mutation))\\n--------\\nImplies(E, Not(D))\\nImplies(solely be determined by the HER2 V777L mutation, Not(trastuzumab resistance))\\n--------\\nImplies(E, Not(C))\\nImplies(solely be determined by the HER2 V777L mutation, Not(directly affect trastuzumab binding to the extracellular kinase domain))\\n--------\\n'}"
        ]
    }
}